Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioAge Labs, Inc. ( (BIOA) ) has issued an update.
On January 21, 2026, BioAge Labs, Inc. priced an upsized underwritten public offering of 5,897,435 shares of common stock at $19.50 per share, for expected gross proceeds of approximately $115.0 million, and entered into an underwriting agreement with Goldman Sachs, Piper Sandler and Citigroup, who were granted a 30-day option to purchase up to an additional 884,615 shares. The company, which expects the offering to close on or about January 23, 2026 subject to customary conditions, anticipates net proceeds of about $107.6 million and plans to use the capital to fund research, clinical and process development and manufacturing for BGE-102 and its NLRP3 and APJ programs, as well as for working capital, capital expenditures, debt reduction and other general corporate purposes, bolstering its financial resources to advance its metabolic disease pipeline.
The most recent analyst rating on (BIOA) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Neutral.
The score is held back most by weak financial performance (large losses and cash burn despite early revenue growth). Offsetting that, technicals show strong upward momentum, and recent positive clinical/pipeline announcements provide supportive catalysts, while valuation remains constrained by loss-making results and no dividend.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
BioAge Labs, Inc., based in Emeryville, California, is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Its lead product candidate, BGE-102, is an orally available, brain-penetrant small-molecule NLRP3 inhibitor in a Phase 1 SAD/MAD trial for cardiovascular risk and retinal diseases, and the company is also advancing long-acting injectable and oral small-molecule APJ agonists for obesity and additional preclinical programs in metabolic aging using its proprietary human longevity data platform.
Average Trading Volume: 605,272
Technical Sentiment Signal: Buy
Current Market Cap: $764.4M
For detailed information about BIOA stock, go to TipRanks’ Stock Analysis page.